Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard Horby, 2020, Dexamethasone in hospitalized patients with Covid-19 - preliminary report, N Engl J Med Cao, 2020, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, 382, 1787, 10.1056/NEJMoa2001282 Simonovich, 2021, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, 384, 619, 10.1056/NEJMoa2031304 Horby, 2020, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, 383, 2030, 10.1056/NEJMoa2022926 Beigel, 2020, Remdesivir for the treatment of Covid-19 - final report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764 Horby, 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial., Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 Praveen, 2020, Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19, Int J Antimicrob Agents, 55, 10.1016/j.ijantimicag.2020.105967 Stebbing, 2020, COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect Dis, 20, 400, 10.1016/S1473-3099(20)30132-8 Bronte, 2020, Baricitinib restrains the immune dysregulation in patients with severe COVID-19, J Clin Invest, 130, 6409, 10.1172/JCI141772 Cantini, 2020, Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact, J Infect, 81, 318, 10.1016/j.jinf.2020.04.017 Titanji, 2021, Use of baricitinib in patients with moderate to severe coronavirus disease 2019, Clin Infect Dis, 72, 1247, 10.1093/cid/ciaa879 Kalil, 2021, Baricitinib plus remdesivir for the treatment of hospitalized adults with Covid-19. A randomized double-blind placebo-controlled trial, N Engl J Med, 384, 795, 10.1056/NEJMoa2031994 Berlin, 2020, Severe Covid-19, N Engl J Med, 383, 2451, 10.1056/NEJMcp2009575 Sterne, 2020, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, J Am Med Assoc, 324, 1330, 10.1001/jama.2020.17023 Tomazini, 2020, Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial, J Am Med Assoc, 324, 1307, 10.1001/jama.2020.17021 Genovese, 2020, Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis, Lancet Rheumatol, 2, e347, 10.1016/S2665-9913(20)30032-1 Rodriguez-Garcia, 2021, Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study, Rheumatology (Oxford), 60, 399, 10.1093/rheumatology/keaa587 Richardson, 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, 395, e30, 10.1016/S0140-6736(20)30304-4 Seif, 2020, JAK inhibition as a new treatment strategy for patients with COVID-19, Int Arch Allergy Immunol, 181, 467, 10.1159/000508247 Stebbing, 2020, Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients, EMBO Mol Med, 12, 10.15252/emmm.202012697 Stebbing, 2021, JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Sci Adv, 7, 10.1126/sciadv.abe4724